{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:57:19Z","timestamp":1793066239116,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jneuroim.2015.09.008","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T19:08:17Z","timestamp":1443294497000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Body mass index influence interferon-beta treatment response in multiple sclerosis"],"prefix":"10.1016","volume":"288","author":[{"given":"Silje Stokke","family":"Kvistad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trygve","family":"Holm\u00f8y","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u016brat\u0117","family":"\u0160altyt\u0117 Benth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonie G.","family":"Beiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian S.","family":"Bjerve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hovdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Lille\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Midgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren J.","family":"Bakke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika E.","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn V.","family":"Sagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2015.09.008_bb0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ana.21141","article-title":"Environmental risk factors for multiple sclerosis. Part II: noninfectious factors","volume":"61","author":"Ascherio","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0010","article-title":"Influence of body mass index on psychological and functional outcomes in patients with multiple sclerosis: a cross-sectional study","author":"Cambil-Martin","year":"2014","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0015","doi-asserted-by":"crossref","first-page":"T47","DOI":"10.1530\/JOE-13-0339","article-title":"Adipocytokines in obesity and metabolic disease","volume":"220","author":"Cao","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0020","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1212\/01.WNL.0000032256.35561.D6","article-title":"A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS","volume":"59","author":"Clanet","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0025","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1177\/1352458512436596","article-title":"High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women","volume":"18","author":"Hedstrom","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075021","article-title":"Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity","volume":"8","author":"Holmoy","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063480","article-title":"Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis","volume":"8","author":"Kalincik","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0040","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/01.WNL.0000145561.08973.4F","article-title":"Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials","volume":"63","author":"Kappos","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00394-008-0700-4","article-title":"Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index","volume":"47","author":"Konradsen","year":"2008","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0050","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/WNL.0b013e31828154f3","article-title":"Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome","volume":"80","author":"Langer-Gould","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P","volume":"46","author":"Li","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1172\/JCI29881","article-title":"Obesity induces a phenotypic switch in adipose tissue macrophage polarization","volume":"117","author":"Lumeng","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0404.2010.01436.x","article-title":"Association between comorbidity and clinical characteristics of MS","volume":"124","author":"Marrie","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0070","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1210\/jcem.87.3.8351","article-title":"IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?","volume":"87","author":"Meier","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/1352458510379243","article-title":"Altered M1\/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration","volume":"17","author":"Mikita","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0080","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1212\/WNL.0b013e3181c0d6e0","article-title":"Body size and risk of MS in two cohorts of US women","volume":"73","author":"Munger","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb5555","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/1352458513483889","article-title":"Childhood body mass index and multiple sclerosis risk: a long-term cohort study","volume":"19","author":"Munger","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0090","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/cyto.1996.0054","article-title":"Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment","volume":"8","author":"Nicoletti","year":"1996","journal-title":"Cytokine"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0095","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s10072-005-0498-2","article-title":"Multiple sclerosis and lifestyle factors: the Hordaland Health Study","volume":"26","author":"Nortvedt","year":"2005","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0100","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O'connor","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nut.2013.08.001","article-title":"Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress","volume":"30","author":"Oliveira","year":"2014","journal-title":"Nutrition"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11910-012-0293-4","article-title":"Modifiable comorbidities and disability in multiple sclerosis","volume":"12","author":"Overs","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0115","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","article-title":"Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6","volume":"69","author":"Park","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0130","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1474-4422(14)70041-9","article-title":"Multiple sclerosis genetics","volume":"13","author":"Sawcer","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/14397595.2013.852837","article-title":"Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus","volume":"24","author":"Shimada","year":"2014","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0140","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12888-014-0327-3","article-title":"Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis","volume":"14","author":"Taylor","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0145","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneurol.2012.283","article-title":"Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Torkildsen","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0150","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/jnnp.62.2.200-b","article-title":"Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist","volume":"62","author":"Voltz","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0160","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/1352458512457845","article-title":"Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica","volume":"19","author":"Wang","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0165","article-title":"Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study","author":"Wesnes","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0170","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/oby.20695","article-title":"Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss","volume":"22","author":"Witasp","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jneuroim.2015.09.008_bb0175","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/ajcn\/72.3.690","article-title":"Decreased bioavailability of vitamin D in obesity","volume":"72","author":"Wortsman","year":"2000","journal-title":"Am. J. Clin. Nutr."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815300436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815300436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:26:50Z","timestamp":1759048010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572815300436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":35,"alternative-id":["S0165572815300436"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.09.008","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body mass index influence interferon-beta treatment response in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}